Allogene Therapeutics (ALLO) Leases (2018 - 2026)

Allogene Therapeutics' Leases history runs 9 years deep, the most recent figure standing at $38.8 million for Q1 2026.

• In Q1 2026, Leases fell 11.93% year-over-year to $38.8 million; the TTM figure through Mar 2026 stood at $38.8 million (down 11.93% YoY), while the FY2025 annual figure was $39.9 million, down 11.76% from the prior year.
• Leases came in at $38.8 million for Q1 2026 at Allogene Therapeutics, down from $39.9 million in the prior quarter.
• In the past five years, Leases ranged from a high of $86.8 million in Q2 2022 to a low of $7.5 million in Q2 2024.
• A 5-year average of $56.0 million and a median of $57.1 million in 2022 frame the typical range for Leases.
• Across the five-year window, Leases tumbled 90.66% in 2024 and soared 459.55% in 2025, its largest moves.
• Allogene Therapeutics' Leases stood at $83.6 million in 2022, then slipped by 23.79% to $63.7 million in 2023, then retreated by 29.04% to $45.2 million in 2024, then dropped by 11.76% to $39.9 million in 2025, then slipped by 2.68% to $38.8 million in 2026.
• According to Business Quant data, Leases over the past three periods registered $38.8 million, $39.9 million, and $40.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison